natgillin/translations-raw huggingface dataset:
2 Viral relapse rates are calculated with a denominator of patients with undetectable HCV RNA at actual EOT.
2 Stope virološkog relapsa izračunate su s nazivnikom koji predstavlja broj bolesnika s nedetektabilnom HCV RNK pri stvarnom kraju liječenja.
Daclatasvir 60 mg once daily daclatasvir AUC 1.96 (1.84-2.10) ↑ daclatasvir Cmax 1.50 (1.39-1.62) ↑ daclatasvir Cmin 2.68 (2.42-2.98) ↑ simeprevir AUC 1.44 (1.32-1.56) ↑ simeprevir Cmax 1.39 (1.27-1.52) ↑ simeprevir Cmin 1.49 (1.33-1.67) ↑
60 mg jedanput na dan daklatasvir AUC 1,96 (1,84-2,10) ↑ daklatasvir Cmax 1,50 (1,39-1,62) ↑ daklatasvir Cmin 2,68 (2,42-2,98) ↑ simeprevir AUC 1,44 (1,32-1,56) ↑ simeprevir Cmax 1,39 (1,27-1,52) ↑ simeprevir Cmin 1,49 (1,33-1,67) ↑
Triazolam (oral)
Triazolam (peroralno) Nije ispitano.
Antimycobacterials Bedaquiline
Lijekovi za liječenje infekcija mikobakterijama
Table 14: Treatment outcome in HCV genotype 1 infected patients without cirrhosis receiving 12 weeks simeprevir + sofosbuvir, with or without ribavirin (study HPC2002) Treatment outcome simeprevir + sofosbuvir N = 21 % (n/N)
Tablica 14: Ishod liječenja u bolesnika inficiranih HCV genotipom 1 bez ciroze koji su primali 12 tjedana simeprevir + sofosbuvir, s ili bez ribavirina (ispitivanje HPC2002)
Budesonide Fluticasone Methylprednisolone Prednisone
Budezonid Flutikazon Metilprednizolon Prednizon
(intestinal CYP3A4 enzyme and P-gp transporter inhibition)
(inhibicija intestinalnog enzima CYP3A4 i P-gp prijenosnika)
Table 23 shows the response rates in HCV genotype 4 infected patients.
U tablici 23 prikazane su stope odgovora u bolesnika inficiranih HCV genotipom
Baseline HCV RNA levels > 800,000 IU/ml
BMI ≥ 30 kg/m2 Medijan razina početnih HCV RNA (log10 IU/ml)
Genotype 4, treatment-naïve or treatment-experienced2, with compensated cirrhosis or without cirrhosis
Genotip 4, prethodno neliječeni ili prethodno liječeni 2, s kompenziranom cirozom ili bez ciroze
Genotype 1, treatment-naïve or treatment-experienced2, without cirrhosis
Genotip 1, prethodno neliječeni ili prethodno liječeni2, bez ciroze
24 weeks3
24 tjedna OLYSIO
Efficacy in treatment-experienced patients with HCV genotype 1 infection In study HPC3007 (PROMISE), patients who relapsed after prior IFN-based therapy received simeprevir (150 mg once daily) + peginterferon alfa-2a + ribavirin for 12 weeks, followed by 12 or 36 additional weeks of peginterferon alfa-2a + ribavirin (see tables 17 and 18).
Djelotvornost u bolesnika s infekcijom HCV genotipom 1 koji su prethodno bili liječeni U ispitivanju HPC3007 (PROMISE), bolesnici koji su doživjeli relaps nakon prethodne terapije temeljene na IFN primali su simeprevir (150 mg jedanput dnevno) + peginterferon alfa-2a + ribavirin tijekom 12 tjedana, nakon čega je slijedilo 12 ili 36 dodatna tjedna peginterferona alfa-2a + ribavirina (vidjeti tablice 17 i 18).
Outcome for patients without SVR12 On-treatment failure2
Ishod za bolesnike bez SVR12
GLUCOCORTICOIDS Dexamethasone (systemic)
Deksametazon (sistemski)
Refer to table 3 for treatment stopping rules based on HCV RNA levels at weeks 4, 12 and 24 for patients receiving treatment with OLYSIO, peginterferon alfa and ribavirin.
Pogledajte tablicu 3 za pravila prekida liječenja temeljena na razinama HCV RNK u 4., 12. i 24.
(OATP1B1/3 transporter inhibition)
(inhibicija OATP1B1/3 prijenosnika)
Genotype 1, treatment-naïve or treatment-experienced2, with compensated cirrhosis
Genotip 1, prethodno neliječeni ili prethodno liječeni 2, s kompenziranom cirozom
Ranitidine
Bedakilin
HCV geno/subtype and presence of baseline Q80K polymorphism in HCV genotype 1a HCV genotype 1a with Q80K
HCV geno/podtip i prisutnost početnog Q80K polimorfizma u HCV genotipu 1a
NAME OF THE MEDICINAL PRODUCT OLYSIO 150 mg hard capsules simeprevir
NAZIV LIJEKA OLYSIO 150 mg tvrde kapsule simeprevir
Table 22: Treatment outcome in HCV genotype 1 infected patients with HIV-1 co-infection
Tablica 22: Ishod liječenja u bolesnika inficiranih HCV genotipom 1 i koinfekcijom HIV-om-1 (ispitivanje C212)
300 mg once daily tenofovir AUC 1.18 (1.13-1.24) ↔ tenofovir Cmax 1.19 (1.10-1.30) ↑ tenofovir Cmin 1.24 (1.15-1.33) ↑ simeprevir AUC 0.86 (0.76-0.98) ↓ simeprevir Cmax 0.85 (0.73-0.99) ↓ simeprevir Cmin 0.93 (0.78-1.11) ↓
Tenofovir dizoproksil fumarat 300 mg jedanput na dan tenofovir AUC 1,18 (1,13-1,24) ↔ tenofovir Cmax 1,19 (1,10-1,30) ↑ tenofovir Cmin 1,24 (1,15-1,33) ↑ simeprevir AUC 0,86 (0,76-0,98) ↓ simeprevir Cmax 0,85 (0,73-0,99) ↓ simeprevir Cmin 0,93 (0,78-1,11) ↓
Simeprevir in combination with peginterferon alfa and ribavirin: During the first 12 weeks treatment with simeprevir, dyspnoea was reported in 11.8% of simeprevir-treated patients, compared to 7.6% in placebo-treated patients (all grades; pooled phase 3).
Dispneja Simeprevir u kombinaciji s peginterferonom alfa i ribavirinom: Tijekom prvih 12 tjedana liječenja simeprevirom, dispneja je bila prijavljena u 11,8% bolesnika liječenih simeprevirom, u usporedbi sa 7,6% bolesnika liječenih placebom (svi stupnjevi; objedinjeno za fazu 3).
Eighty-nine percent (54/61) of the simeprevir-treated treatment-naïve patients and prior relapsers without cirrhosis were eligible for 24 weeks of treatment; in these patients the SVR12 rate was 87%.
Osamdeset i devet posto (54/61) bolesnika bez ciroze liječenih simeprevirom, koji prethodno nisu bili liječeni ili su prethodno doživjeli relaps bilo je pogodno za 24 tjedna liječenja; u tih bolesnika stopa
sofosbuvir N = 286 n (%)
12 tjedana simeprevir + sofosbuvir N = 286 n (%)
It is not recommended to co-administer OLYSIO with these anticonvulsants as co-administration may result in loss of therapeutic effect of OLYSIO.
Ne preporučuje se istovremeno primjenjivati lijek OLYSIO s ovim antikonvulzivima jer istovremena primjena može dovesti do gubitka terapijskog učinka lijeka
NARCOTIC ANALGESICS Methadone7
Metadon7
Short term monotherapy data of simeprevir from studies C201 (genotype 1) and C202 (genotype 2, 3, 4, 5 and 6) in patients receiving 200 mg once daily simeprevir for 7 days is presented in table 9.
(genotip 2, 3, 4, 5 i 6) u bolesnika koji uzimaju 200 mg simeprevira jedanput na dan tijekom 7 dana prikazani su u tablici 9.
Felodipine
Felodipin
LIST OF EXCIPIENTS Contains lactose monohydrate
Sadrži laktozu hidrat
Recommendation for co-administration
Preporuke za istovremenu primjenu
Tacrolimus 2 mg patient individualised dose4
Takrolimus 2 mg
Mild increases in simeprevir concentrations may occur due to mild inhibition of OATP1B1 by sildenafil.
Moguća su blaga povišenja koncentracija PDE-5 inhibitora u plazmi. (inhibicija intestinalnog enzima CYP3A4) Mogu se javiti blaga povišenja koncentracija simeprevira zbog blage inhibicije OATP1B1 sildenafilom.
Table 19 shows the response rates in HCV genotype 1 infected treatment-naïve patients.
Tablica 19 pokazuje stope odgovora u bolesnika inficiranih HCV genotipom 1 koji prethodno nisu bili liječeni.
2 Viral relapse rates are calculated with a denominator of patients with undetectable HCV RNA at actual EOT and with at least one follow-up HCV RNA assessment.
2 Stope virološkog relapsa izračunavaju se s nazivnikom koji predstavlja broj bolesnika s nedetektabilnom HCV RNK pri stvarnom kraju liječenja i s barem jednim praćenjem s procjenom HCV RNK.
The recommended co-administered medicinal product(s) and treatment duration for OLYSIO combination therapy are provided in tables 1 and 2.
Preporučeni istovremeno primijenjeni lijek(ovi) i trajanje liječenja u kombiniranom liječenju s lijekom
In HCV genotype 1a infected patients with cirrhosis, testing for the presence of the NS3 Q80K polymorphism may be considered prior to initiation of therapy with OLYSIO in combination with sofosbuvir (see section 5.1).
Prije početka liječenja lijekom OLYSIO u kombinaciji sa sofosbuvirom u bolesnika s infekcijom HCV genotipa 1a s cirozom može se uzeti u obzir ispitivanje na prisutnost NS3 Q80K polimorfizma (vidjeti dio 5.1).
Prior non-responder patients (including partial and null responders) with or without cirrhosis, with or without HIV co-infection
s ili bez ciroze, s ili bez koinfekcije HIV-om
STATEMENT OF ACTIVE SUBSTANCE(S) Each hard capsule contains simeprevir sodium equivalent to 150 mg simeprevir.
Jedna tvrda kapsula sadrži simeprevirnatrij što odgovara 150 mg simeprevira.
Fertility
Terfenadin
90% confidence interval of the geometric mean ratio being within (↔), below (↓) or above (↑) the 0.80 - 1.25 range.
Smjer strjelice (↑ = povišenje, ↓ = sniženje, ↔ = bez promjene) za svaki farmakokinetički parametar temelji se na intervalu pouzdanosti od 90% omjera geometrijske srednje vrijednosti koji je unutar (↔), ispod (↓) ili iznad (↑) raspona od 0,80
Prior relapsers
Bolesnici s prethodnim relapsom
WHO toxicity range1
Raspon toksičnosti prema
SOC
Osip
Genotype 1, treatment-naïve or treatment-experienced4, HCV/HIV-1 co-infected patients, with compensated cirrhosis or without cirrhosis treatment-naïve patients or prior relapsers without cirrhosis: 12 weeks SMV + peg-IFN-alfa + RBV, followed by 12 or 36 weeks peg-IFN-alfa + RBV prior non-responder patients (partial and null responders) without cirrhosis and all treatment-naïve and treatment-experienced patients with cirrhosis: 12 weeks SMV + peg-IFN-alfa + RBV, followed by 36 weeks peg-IFN-alfa + RBV
Genotip 1, prethodno neliječeni ili prethodno liječeni4, HCV/HIV-1 koinficirani bolesnici, s kompenziranom cirozom ili bez ciroze prethodno neliječeni bolesnici ili bolesnici s prethodnim relapsom bez ciroze: 12 tjedana SMV +
Genotype 1, treatment-naïve or null responders3, with compensated cirrhosis or without cirrhosis
Genotip 1, prethodno neliječeni ili koji nisu odgovorili na liječenje3, s kompenziranom cirozom ili bez ciroze
(intestinal CYP3A4 enzyme inhibition)
(inibicija intestinalnog enzima CYP3A4)
Treatment with OLYSIO must be initiated in combination with peginterferon alfa + ribavirin and administered for 12 weeks and then followed by an additional 36 weeks of peginterferon alfa and + ribavirin.
12 tjedana nakon čega slijedi dodatnih 36 tjedana peginterferona alfa i + ribavirina.
Buprenorphine Naloxone
Buprenorfin Nalokson
Pooled phase 3 studies simeprevir + peginterferon alfa + ribavirin N = 152 n (%)
simeprevir + peginterferon alfa + ribavirin N = 152 n (%)
Treatment with OLYSIO must be initiated in combination with peginterferon alfa + ribavirin and administered for 12 weeks and then followed by an additional 12 weeks of peginterferon alfa + ribavirin.
Liječenje lijekom OLYSIO mora se započeti u kombinaciji s peginterferonom alfa + ribavirinom i primijeniti tijekom
Outcome for patients without SVR12 On-treatment failure Viral relapse1
Ishod za bolesnike bez SVR12 Neuspjeh tijekom liječenja1
Median baseline HCV RNA levels (log10 IU/ml) Presence of cirrhosis no cirrhosis with cirrhosis Prior treatment history treatment-naïve treatment-experienced1 IL28B genotype CC non-CC HCV geno/subtype and presence of baseline Q80K polymorphism in HCV genotype 1a HCV genotype 1a with Q80K HCV genotype 1b
IL28B genotip CC ne-CC HCV geno/subtip i prisutnost početnog Q80K polimorfizma u HCV genotipu 1a HCV genotip 1a s Q80K HCV genotipe 1b
Significant decrease in plasma concentrations of simeprevir are expected.
Očekuju se značajna sniženja koncentracije simeprevira u plazmi. (indukcija enzima CYP3A4)
4 Viral relapse rates are calculated with a denominator of patients with undetectable HCV RNA at EOT and with at least one follow-up HCV RNA assessment.
4 Stope virološkog relapsa izračunate su s nazivnikom koji predstavlja broj bolesnika s nedetektabilnom HCV RNA na završetku liječenja i s najmanje jednom procjenom HCV RNA tijekom praćenja.
1 Viral relapse rates are calculated with a denominator of patients with undetectable HCV RNA at EOT and with at least one follow-up HCV RNA assessment.
1 Stope virološkog relapa izračunate su s nazivnikom koji predstavlja broj bolesnika s nedetektabilnom HCV RNA na završetku liječenja i s najmanje jednom procjenom HCV RNA tijekom praćenja.
Grade 2 ‘blood bilirubin increased' was reported in one patient (0.3%) receiving 12 weeks of treatment.
‘Povišen bilirubin u krvi' 2. stupnja bio je prijavljen u jednog bolesnika
Treatment with OLYSIO must be initiated in combination with peginterferon alfa + ribavirin and administered for 12 weeks and then followed by an additional 36 weeks of peginterferon alfa + ribavirin.
12 tjedana nakon čega slijedi dodatnih 36 tjedana peginterferona alfa + ribavirina.
Significant increases in plasma concentrations of simeprevir are expected.
Očekuju se značajna povišenja koncentracije simeprevira u plazmi. (blaga do umjerena inhibicija enzima CYP3A4)
Nisoldipine
Nizoldipin
2 Viral relapse rates are calculated with a denominator of patients with undetectable HCV RNA at EOT and with at least one follow-up HCV RNA assessment.
2 Stope virološkog relapsa izračunate su s nazivnikom koji predstavlja broj bolesnika s nedetektabilnom HCV RNA na završetku liječenja i s najmanje jednom procjenom HCV RNA praćenja.
Prior treatment history treatment-naïve treatment-experienced2
Anamneza prethodnog liječenja prethodno neliječeni prethodno liječeni2
1 Includes relapsers, partial and null reponders to prior treatment with interferon (pegylated or non-pegylated), with or without ribavirin, and interferon-intolerant patients.
1 Uključuje bolesnike s relapsom, djelomičnim odgovorom ili bez odgovora na prethodno liječenje s interferonom
Genotype 1, treatment-naïve patients, with compensated cirrhosis or without cirrhosis
Genotip 1, prethodno neliječeni, s kompenziranom cirozom ili bez ciroze
Significantly decreased plasma concentrations of simeprevir are expected.
Očekuju se značajno snižene koncentracije simeprevira u plazmi. (indukcija enzima CYP3A4)
Powder: 500 U; Solvent: 5 ml
Prašak: 500 U; Otapalo: 5 ml
500 U Powder and solvent for solution for injection
500 U Prašak i otapalo za otopinu za injekciju
Intravenous use powder: vial (glass); solvent: vial (glass)
Primjenu u venu prašak: bočica (staklo); otapalo:
2 powder vials 2 solvent vials 2 filter transfer devices
2 bočice s praškom 2 bočice s otapalom 2 uređaja za prijenos s filtrom2 štrcaljke od 10 ml za jednokratnu uporabu 2 seta za venepunkciju 2 zaštitne podloge
MA (EU) number (Invented) name Strength Pharmaceutical Form
Zaštićeno ime Doza Farmaceutski oblik Put primjene Unutarnje pakovanje
It may be used:
Može se koristiti:
The veterinarian will decide if additional treatment is needed.
Veterinar će odlučiti je li potrebno dodatno liječenje.
This product is harmful if swallowed.
Ovaj je proizvod štetan ako se proguta.
This summary was last updated in September 2019.
Sažetak je posljednji put ažuriran u rujnu 2019.
This includes cuddling the animal and sharing a bed with the animal.
To uključuje maženje životinje i dijeljenje kreveta sa životinjom.
It takes up to 48 hours for the application site to become dry but it will be noticeable for longer.
Potrebno je do 48 sati dok se mjesto primjene osuši, ali će biti vidljivo i duže.
Further information on Bravecto can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/bravecto.
Više informacija o VMP-u Bravecto dostupno je na internetskim stranicama Agencije: ema.europa.eu/medicines/veterinary/EPAR/bravecto.
Contact with skin and/or eyes should be avoided including hand to eye contact.
Potrebno je izbjegavati kontakt s kožom i/ili očima, uključujući kontakt očiju s rukom.
What is Bravecto and what is it used for?
Što je Bravecto i za što se koristi?
People handling the medicine should not smoke, eat or drink and should wash their hands thoroughly after handling the product.
Osobe koje rukuju ovim VMP-om ne smiju pušiti, jesti niti piti i trebaju temeljito oprati ruke nakon rukovanja ovim proizvodom.
The animal's application site should no longer be noticeable before resuming contact with the site of application.
Mjesto primjene na životinji više ne bi smjelo biti vidljivo prije ponovnog dodira s mjestom primjene.
Used pipettes should be disposed of immediately.
Rabljene pipete potrebno je odmah zbrinuti.
Bravecto spot-on solution should be kept away from heat, sparks, open flames or other fire sources as it is highly flammable.
Bravecto potrebno je držati dalje od izvora topline, iskri, otvorenog plamena ili drugih izvora vatre jer je vrlo zapaljiva.
For ear mite infestations, a veterinary check is advised 28 days after treatment.
Za infestacije ušnim šugarcem savjetuje se kontrola veterinara 28 dana nakon liječenja.
Other information about Bravecto
Ostale informacije o VMP-u Bravecto
It blocks the normal movement of charged chloride particles (ions) in and out of nerve cells, especially those associated with gamma-aminobutyric acid (GABA) and glutamate, two substances that convey messages between nerves (neurotransmitters).
Inhibira normalno kretanje nabijenih čestica klorida (iona) u živčane stanice i iz njih, posebno kad je riječ o onima povezanim s gama-aminomaslačnom kiselinom (GABA) i glutamatom, dvjema tvarima koje prenose poruke između živaca (neurotransmiteri).
Why is Bravecto authorised in the EU?
Zašto je Bravecto odobren u EU-u?
Bravecto can only be obtained with a prescription.
Bravecto se izdaje samo na recept.
This means that it kills parasites that live on or in the skin or in the fur or ears of animals, such as fleas, ticks and mites.
To znači da ubija parazite koji žive na koži ili u dlaci ili ušima životinja, kao što su buhe, krpelji i grinje.
What are the risks associated with Bravecto?
Koji su rizici povezani s VMP-om Bravecto?
The product should be kept in the original package until use, in order to prevent children directly accessing the medicine.
Do trenutka primjene proizvod se mora čuvati u originalnoj ambalaži kako bi se spriječio izravan pristup djece VMP-u.
Fluralaner kills fleas, ticks and mites that have ingested the dog's or cat's blood by acting on their nervous system.
Fluralaner ubija buhe, krpelje i grinje koji su se nahranili psećom ili mačjom krvlju tako što djeluje na njihov živčani sustav.
The main measure of effectiveness was the reduction in the number of fleas and ticks in the infested dogs during the 3 months after receiving treatment.
Glavno mjerilo učinkovitosti bilo je smanjenje broja buha i krpelja u infestiranih pasa tijekom tri mjeseca nakon primjene terapije.
The effectiveness of Bravecto against fleas and ticks was investigated in both laboratory and field studies.
Učinkovitost VMP-a Bravecto protiv buha i krpelja ispitana je i u laboratorijskim i u terenskim ispitivanjima.
The European Medicines Agency decided that Bravecto's benefits are greater than its risks and it can be authorised for use in the EU.
Europska agencija za lijekove zaključila je da koristi od VMP-a Bravecto nadmašuju s njim povezane rizike te se može izdati odobrenje za njegovu primjenu u EU-u.
For dogs, several spots may be applied from the initial spot in a line to the base of the tail.
U pasa se može primijeniti na nekoliko mjesta u nizu od početnog mjesta do korijena repa.
In a study conducted in the EU involving cats with ear mites, the effectiveness of Bravecto was >90% based on presence of live ear mites at day 28 after treatment.
U ispitivanju provedenom u EU-u na mačkama s ušnim šugarcima, učinkovitost VMP-a Bravecto iznosila je >90 %, na temelju prisutnosti ušnih šugaraca 28. dana nakon liječenja.
In case of spillage on table or floor surfaces, excess Bravecto spot-on solution should be removed using paper tissue and the area cleaned with a detergent.
U slučaju izlijevanja na površinu stola ili poda, višak otopine Bravecto za nakapavanje potrebno je ukloniti papirnatom maramicom, a površinu očistiti deterdžentom.
An overview of Bravecto and why it is authorised in the EU
Pregled informacija o VMP-u Bravecto i zašto je odobren u EU-u
For optimal tick control, treatment should be repeated every 8 to 12 weeks depending on the tick species.
Za optimalnu kontrolu protiv krpelja terapiju je potrebno ponoviti svakih 8 do 12 tjedana ovisno o vrsti krpelja.
If skin contact occurs, the affected area should be washed immediately with soap and water
Ako dođe do kontakta s kožom, zahvaćeno područje potrebno je odmah oprati sapunom i vodom.
The active substance in Bravecto, fluralaner, acts as an ‘ectoparasiticide'.
Djelatna tvar u VMP-u Bravecto, fluralaner, djeluje kao „ektoparaziticid”.
Bravecto received a marketing authorisation valid throughout the EU on 11 February 2014.
Za VMP Bravecto izdano je odobrenje za stavljanje u promet koje je na snazi u EU-u od 11. veljače
In order to be exposed to the active substance, parasites must attach to the skin and commence feeding on the dog or cat.
Kako bi ih se izložilo djelatnoj tvari, paraziti se moraju primiti za kožu i započeti hranjenje krvlju psa ili mačke.
As demodectic mange is caused by a number of factors, it is advisable for any underlying disease to be treated.
Budući da postoji niz uzroka demodikoze, savjetuje se liječenje eventualne/ih osnovne/ih bolesti.
Because parasites must start feeding on the dog or cat in order to be killed by the medicine, they might still be able to transmit any diseases with which they may be infected.
Budući da se paraziti moraju početi hraniti krvlju psa ili mačke da bi ih se moglo iskorijeniti VMP-om, ne može se isključiti rizik od prijenosa bolesti kojima oni mogu biti zaraženi.
Fluralaner kills fleas before they can lay eggs and so helps to reduce contamination of the dogs' or cats' environment.
Fluralaner ubija buhe prije nego što one izlegnu jajašca te tako pomaže u smanjivanju kontaminacije okruženja psa ili mačke.
Bravecto spot-on solution and the wet skin of a recently treated animal may be slightly irritating to skin and/or eyes.
Otopina za nakapavanje Bravecto i mokra koža nedavno tretirane životinje mogu biti blago nadražujući za kožu i/ili oči.
In cats, Bravecto kills fleas within 12 hours and ticks within 48 hours.
U mačaka, Bravecto ubija buhe unutar 12 sati, a krpelje unutar 48 sati.
• to treat demodectic and sarcoptic mange (skin infestation caused by two different mites) in dogs
• za liječenje demodikoze i sarkoptoze (infestacija kože koje uzrokuju dvije različite vrste grinja) u pasa
Bravecto kills fleas within 8 hours and ticks within 12 hours in dogs.
Bravecto ubija buhe u roku od 8 sati, a krpelje u roku od 12 sati u pasa.
In case of eye contact, the affected area should be rinsed immediately with water.
U slučaju kontakta s očima, zahvaćeno područje potrebno je odmah isprati vodom.
Bravecto is a veterinary medicine used to treat parasitic infestations in dogs and cats.
Bravecto je veterinarsko-medicinski proizvod koji se koristi za liječenje infestacije pasa i mačaka parazitima.
How does Bravecto work?
Kako djeluje Bravecto?
The spot-on solution and tablets are available in different strengths for dogs and cats of different weights.
Otopina za nakapavanje i tablete dostupne su u različitim jačinama za primjenu u pasa i mačaka različitih težina.
The most common side effects of the tablets in dogs (which may affect more than 1 in 100 animals) are mild and short-lived diarrhoea, vomiting, lack of appetite and drooling.
Najčešće su nuspojave tableta u pasa (mogu se javiti u više od 1 na 100 životinja) blag i kratkotrajan proljev, povraćanje, gubitak apetita i slinjenje.
Bravecto contains the active substance fluralaner.
VMP Bravecto sadrži djelatnu tvar fluralaner.
If the product is accidentally swallowed by a person, the advice of a doctor should be sought immediately and the package leaflet or label shown to the doctor.
Ako osoba slučajno proguta ovaj proizvod, potrebno je odmah potražiti liječnički savjet te liječniku pokazati uputu o VMP-u ili njegovu etiketu.
• as part of the management of flea allergy dermatitis (an allergic reaction to flea bites) in dogs and cats
• kao dio liječenja alergijskog dermatitisa koji uzrokuju buhe (alergijske reakcije na ugrize buha) u pasa i mačaka
Bravecto was effective against fleas and ticks for up to 12 weeks after treatment, and was as effective as fipronil in terms of the percentage of dogs and cats as well as households free of fleas and ticks.
VMP Bravecto pokazao se učinkovitim protiv buha i krpelja do 12 tjedana nakon primjene terapije i jednako učinkovitim kao fipronil u pogledu postotka pasa i mačaka te kućanstava bez buha i krpelja.